2020 - ESSA Pharma

Date	Title
November 25, 2020	ESSA Pharma to Participate at Evercore ISI 3rd Annual HealthCONx Conference
November 10, 2020	ESSA Pharma to Participate in Upcoming Investor Conferences
October 26, 2020	ESSA Pharma Inc. Announce the Delisting from the TSX-V
October 24, 2020	ESSA Pharma Presents Therapeutic Potential of EPI-7386 at 32nd EORTC-NCI-AACR Symposium
October 19, 2020	ESSA Pharma Announces Multiple Abstracts Accepted for Presentation at Upcoming Medical and Scientific Symposia
September 21, 2020	ESSA Pharma to Participate in Oppenheimer Fall Healthcare Life Science & MedTech Summit
September 17, 2020	ESSA Pharma Announces the Presentation of Additional Preclinical Data for EPI-7386 at the ESMO Virtual Congress 2020
September 14, 2020	ESSA Pharma Announces Fast Track Designation Granted by the FDA to EPI-7386 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
September 10, 2020	ESSA Pharma to Participate in Multiple Upcoming Investor Conferences
August 6, 2020	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2020